NCT05214326View on ClinicalTrials.gov

A Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Male and Female Participants of Atleast 12 Years Old Receiving Dupilumab Injections in Gulf Countries

CompletedOBSERVATIONAL
Enrollment

187

Participants

Timeline

Start Date

January 18, 2022

Primary Completion Date

March 21, 2023

Study Completion Date

March 21, 2023

Conditions
Dermatitis Atopic
Trial Locations (3)

Unknown

Investigational site Kuwait, Kuwait City

Investigational site Saudi Arabia, Saudi Arabia

Investigational site United Arab Emirates, United Arab Emirates

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT05214326 - A Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Male and Female Participants of Atleast 12 Years Old Receiving Dupilumab Injections in Gulf Countries | Biotech Hunter | Biotech Hunter